Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Background: The low Fermentable Oligo‐, Di‐ Monosaccharides, and Polyoles ( FODMAP ) diet is a new treatment option for irritable bowel syndrome ( IBS ). Experts refer to the diet as supported by high level of evidence, but an evaluation of the quality of trials is lacking. Aim: To provide a systematic review of the quality of trials on the symptomatic effects of the low FODMAP diet for IBS . Methods: Pubmed and EMBASE were searched for randomised controlled trials ( RCT s) reporting effect of the low FODMAP diet on IBS symptoms. The quality of trials was evaluated by estimating risk of bias and assessing trial methodology. Results: Nine RCT s were eligible, including 542 patients. The intervention period was from 2 days to 6 weeks and one trial included a 6‐month follow‐up. Three trials intervened by providing meals, controlling with a diet high in FODMAP content. In six trials, the intervention was instruction by a dietician and a variety of control interventions were used, all with limited established efficacy. Domains with a high risk of bias were identified for all the trials. High risk of bias dominated domains regarding blinding, with only one trial double‐blinded. Conclusions: The RCT s on the low FODMAP diet are characterized by high risk of bias. The diet has not been studied in a randomised, controlled setting for more than 6 weeks and trials examining the effect of the important reintroduction period are lacking. There is a risk that the symptomatic effects reported in the trials are driven primarily by a placebo response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Böhn, L., Störsrud, S., Törnblom, H., Bengtsson, U., & Simrén, M. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.105 · Cited by 655
Staudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.159285 · Cited by 590 · cited 3×
“This might impact negatively on the patients’ expectations to symptom improvement as reflected by symptom deterioration in the control group at follow-up in the trial by Staudacher et al.19 In the trial by Pedersen et al.,18 the other control group was allocated to treatment with a probiotic not previously tested in I…”
Ong, D. K., Mitchell, S. B., Barrett, J. S., Shepherd, S. J., Irving, P. M., Biesiekierski, J. R., Smith, S., Gibson, P. R., & Muir, J. G. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06370.x · Cited by 583 · cited 7×
“Three trials used a crossover design.(9,17,20) In the study by Halmos et al.”
InfluentialDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Chumpitazi, B. P., Cope, J. L., Hollister, E. B., Tsai, C. M., McMeans, A. R., Luna, R. A., Versalovic, J., & Shulman, R. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13286 · Cited by 436
Monsbakken, K. W., Vandvik, P. O., & Farup, P. G. (2006) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602367 · Cited by 364
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285 · cited 1×
“There is a high placebo response in treatment trials of IBS patients, regardless of the character of the intervention.(28) The placebo response ranges from 3% to 84% in published IBS treatment trials.”
Effect of interpretive bias on research evidence
Kaptchuk, T. J. (2003) · BMJ · doi:10.1136/bmj.326.7404.1453 · Cited by 222
Halpert, A., Dalton, C. B., Palsson, O., Morris, C., Hu, Y., Bangdiwala, S., Hankins, J., Norton, N., & Drossman, D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01254.x · Cited by 184
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Dionne, J., Ford, A. C., Yuan, Y., Chey, W. D., Lacy, B. E., Saito, Y. A., Quigley, E. M. M., & Moayyedi, P. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0195-4 · Cited by 379
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Black, C. J., Staudacher, H. M., & Ford, A. C. (2022) · Gut · doi:10.1136/gutjnl-2021-325214 · Cited by 353
Metadata
- Authors
- Krogsgaard, L. R., Lyngesen, M., & Bytzer, P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-04-25
- Volume
- 45
- Issue
- 12
- Pages
- 1506-1513
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2609972824
- Cited by
- 77
- References
- 14
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. https://app.cochat.ai/papers/10.1111/apt.14065
- The paper
- Krogsgaard, L. R., Lyngesen, M., & Bytzer, P. (2017). Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.